# A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

> **NCT01194570** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 735 (actual)

## Conditions studied

- Multiple Sclerosis, Primary Progressive

## Interventions

- **DRUG:** Ocrelizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01194570
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-02
- **Primary completion:** 2015-07-23
- **Final completion:** 2022-12-31
- **Target enrollment:** 735 (ACTUAL)
- **Last updated:** 2024-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01194570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01194570, "A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01194570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*